Dr. Pep

Peptides · Alpha-MSH C-terminal tripeptide (Lys-Pro-Val)

KPV: what the studies show

Every line below comes from a study, label or regulator record, checked by two models, with the source linked. Information, not medical advice. For adults 18+.

What it is

  • KPV is a three-amino-acid peptide (lysine-proline-valine). It is the last three amino acids of alpha-MSH, a natural hormone that calms inflammation and drives skin pigment. It is not the same as melanotan or alpha-MSH itself.[1][2][3]
  • The body makes the parent hormone alpha-MSH. Papers that show KPV or alpha-MSH working in lab or animal models do not show that KPV sold online reaches or acts on the body the same way.[2][4]

Bottom line

  • All the evidence for KPV is from cells, mice, rats and rabbits, mostly in gut inflammation models. FDA found no published study of KPV in people and no human exposure data by any route.[3][5][4]

What the human studies found

  • No published human study of KPV was found by FDA in its July 2026 briefing document. FDA said no published studies used KPV (free base) or KPV acetate, compounded or not, in humans.[3]
  • Two records in the records we hold are labelled 'human observational' but are not studies of KPV in people. One is a 2015 lab method for measuring KPV in solutions and skin samples. The other is a 2000 test on human white blood cells in a dish, where KPV and related peptides raised killing of Candida and Staphylococcus.[6][7]

Known risks and side effects

  • FDA says it has not identified any human exposure data on drug products containing KPV by any route, and lacks important information on whether KPV would cause harm in humans.[5]
  • FDA found KPV poorly characterised: naming is inconsistent, and no public data on impurities, clumping or microbial testing were found, so what is in a vial is uncertain.[3]
  • In mice, the gut transporter PepT1 that carries KPV also promoted colitis-associated cancer. This is a mouse finding and does not show KPV is risky or safe in people.[8]

Legal status

  • KPV is not an approved drug. FDA's category 2 page (retrieved 2026-10-09) lists it among nominated-but-withdrawn bulk substances and says FDA has no human exposure data.[5]
  • FDA's briefing document for the July 23-24, 2026 advisory committee evaluated KPV for wound healing and inflammatory conditions (0.1% topical cream or gel) and concluded the criteria weigh against adding it to the 503A bulks list. The nomination was withdrawn and FDA evaluated it on its own initiative.[3]
  • ABC News reportedly said the committee narrowly voted to recommend adding KPV and five other peptides to the 503A list, against FDA staff advice. This is a secondary report. FDA had not posted minutes as of 2026-10-09. The vote is advisory and non-binding.[9]

Sources

  1. [1] Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.
  2. [2] Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.
  3. [3] July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate)
  4. [4] Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
  5. [5] FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (503A/503B category 2)
  6. [6] Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.
  7. [7] Antimicrobial effects of alpha-MSH peptides.
  8. [8] Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.
  9. [9] ABC News: FDA advisers narrowly vote to add 6 peptides to drug compounding list (2026-07-24)